Dong Yu Selected Research

Cyclic AMP-Dependent Protein Kinase RIalpha Subunit

7/2002	GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
7/2002	Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dong Yu Research Topics

Disease

28	Neoplasms (Cancer) 12/2021 - 04/2002
26	Infections 07/2021 - 09/2006
7	Virus Diseases (Viral Diseases) 04/2021 - 03/2010
6	Inflammation (Inflammations) 01/2022 - 11/2003
5	Body Weight (Weight, Body) 01/2022 - 11/2004
4	Hypoxia (Hypoxemia) 06/2022 - 11/2007
4	Wounds and Injuries (Trauma) 01/2022 - 11/2008
4	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2012
4	Hypersensitivity (Allergy) 10/2015 - 09/2002
3	Cicatrix (Scar) 01/2022 - 10/2017
3	Breast Neoplasms (Breast Cancer) 01/2020 - 05/2003
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 02/2016
3	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 05/2003
3	Congenital Abnormalities (Deformity) 11/2008 - 03/2006
3	Asthma (Bronchial Asthma) 09/2007 - 09/2002
2	Dyslipidemias (Dyslipidemia) 06/2022 - 01/2022
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 01/2022
2	Cognitive Dysfunction 01/2022 - 01/2022
2	Myocardial Ischemia (Ischemic Heart Diseases) 12/2021 - 07/2018
2	Lung Neoplasms (Lung Cancer) 12/2021 - 07/2002
2	Hemorrhage 07/2021 - 01/2019
2	Communicable Diseases (Infectious Diseases) 04/2021 - 10/2019
2	Emerging Communicable Diseases (Emerging Infectious Diseases) 04/2021 - 10/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 02/2003
2	Atrial Fibrillation 01/2019 - 01/2019
2	Ischemia 07/2018 - 01/2015
2	Pain (Aches) 05/2018 - 02/2010
2	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2009 - 09/2009
2	Colonic Neoplasms (Colon Cancer) 04/2002 - 04/2002
1	Arteriosclerosis 06/2022
1	Atherosclerotic Plaque (Atheroma) 06/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Brugada Syndrome 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Obesity 01/2022
1	Brain Injuries (Brain Injury) 01/2022

Drug/Important Bio-Agent (IBA)

23	Proteins (Proteins, Gene)FDA Link 04/2021 - 02/2003
8	OligonucleotidesIBA 09/2007 - 04/2002
7	VaccinesIBA 04/2021 - 09/2002
7	Antisense OligonucleotidesIBA 09/2006 - 04/2002
6	Pharmaceutical PreparationsIBA 01/2022 - 04/2002
6	DNA (Deoxyribonucleic Acid)IBA 10/2017 - 04/2004
6	Viral DNAIBA 01/2014 - 09/2006
5	Messenger RNA (mRNA)IBA 06/2022 - 09/2006
5	Indicators and Reagents (Reagents)IBA 12/2021 - 02/2015
4	Therapeutic UsesIBA 11/2021 - 04/2002
4	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2017
3	salicylhydroxamic acid (SHAM)IBA 06/2022 - 12/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2003
3	Long Noncoding RNAIBA 12/2021 - 09/2019
3	AntigensIBA 07/2021 - 11/2013
3	Phosphotransferases (Kinase)IBA 01/2012 - 04/2009
3	Viral ProteinsIBA 03/2010 - 09/2006
3	Irinotecan (Camptosar)FDA LinkGeneric 07/2002 - 04/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 09/2006
2	Sodium Channels (Sodium Channel)IBA 01/2022 - 01/2019
2	Cisplatin (Platino)FDA LinkGeneric 12/2021 - 12/2017
2	Competitive Endogenous RNAIBA 01/2021 - 09/2019
2	MicroRNAs (MicroRNA)IBA 10/2020 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 08/2020 - 09/2019
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 12/2015
2	CarbonIBA 01/2020 - 10/2015
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 04/2017 - 08/2002
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 11/2007
2	arseniteIBA 01/2017 - 10/2014
2	Mechanistic Target of Rapamycin Complex 1IBA 08/2015 - 09/2011
2	CytokinesIBA 07/2013 - 04/2013
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2012 - 06/2010
2	AntibodiesIBA 01/2012 - 09/2002
2	EnzymesIBA 09/2009 - 04/2007
2	sulforaphaneIBA 09/2009 - 12/2008
2	OvalbuminIBA 09/2007 - 01/2004
2	Docetaxel (Taxotere)FDA Link 09/2006 - 04/2004
2	AllergensIBA 11/2003 - 09/2002
2	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 07/2002 - 07/2002
2	Antineoplastic Agents (Antineoplastics)IBA 07/2002 - 04/2002
2	Cyclic AMP-Dependent Protein Kinase RIalpha SubunitIBA 07/2002 - 07/2002
2	Topoisomerase I InhibitorsIBA 07/2002 - 04/2002
1	Angiopoietin-Like Protein 4IBA 06/2022
1	Apolipoproteins E (ApoE)IBA 06/2022
1	Saline SolutionIBA 06/2022
1	danlou tabletIBA 06/2022
1	Particulate MatterIBA 01/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2022
1	Galectins (Galectin)IBA 01/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	gamma-Aminobutyric Acid (GABA)IBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 01/2022
1	ResveratrolIBA 01/2022

Therapy/Procedure

12	Therapeutics 11/2021 - 04/2002
5	Radiotherapy 01/2021 - 02/2004
3	Drug Therapy (Chemotherapy) 12/2015 - 09/2006
2	Stents 01/2019 - 08/2018
2	Injections 01/2011 - 05/2009
2	Cardiopulmonary Resuscitation (CPR) 04/2004 - 05/2003
1	Truncal Vagotomy 01/2022
1	Gastrectomy 01/2022
1	Bariatric Surgery 01/2022